The role of tumor necrosis factor-alpha in systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 10, Issue 1, 2008, Pages

  Aringer, Martin ^a   Smolen, Josef S ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 18; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; PLACEBO; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; MONOCLONAL ANTIBODY; PHOSPHOLIPID;

ANTIBODY RESPONSE; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; BACTEREMIA; BACTERIAL INFECTION; CHROMATIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOREGULATION; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; MONOTHERAPY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SKIN LUPUS ERYTHEMATOSUS; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY TRACT INFECTION; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOIMMUNITY; CHROMATIN; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; PHOSPHOLIPIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47049112010     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2341     Document Type: Review

References (76)

1. Theofilopoulos AN Lawson BR Tumour necrosis factor and other cytokines in murine lupus Ann Rheum Dis 1999, 58(Suppl 1):I49-I55 1766580 10577973
2. McDevitt H Munson S Ettinger R Wu A Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity Arthritis Res 2002, 4:S141-S152. 10.1186/ar570 12110133
3. Mageed RA Isenberg DA Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production Lupus 2002, 11:850-855. 10.1191/0961203302lu306rr 12529050
4. Aringer M Smolen JS Complex cytokine effects in a complex autoimmune disease: Tumor necrosis factor in systemic lupus erythematosus Arthritis Res Ther 2003, 5:172-177. 165063 12823847 10.1186/ar770
5. Suryaprasad AG Prindiville T The biology of TNF blockade Autoimmun Rev 2003, 2:346-357. 10.1016/S1568-9972(03)00048-X 14550876
6. Kollias G TNF pathophysiology in murine models of chronic inflammation and autoimmunity Semin Arthritis Rheum 2005, 34:3-6. 10.1016/ j.semarthrit.2005.01.002 15852247
7. Coutinho A Kazatchkine MD Avrameas S Natural autoantibodies Curr Opin Immunol 1995, 7:812-818. 10.1016/0952-7915(95)80053-0 8679125
8. Schwartz M Cohen IR Autoimmunity can benefit self-maintenance Immunol Today 2000, 21:265-268. 10.1016/S0167-5699(00)01633-9 10825737
9. Jacob CO McDevitt HO Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis Nature 1988, 331:356-358. 10.1038/331356a0 2893286
10. Gordon C Ranges GE Greenspan JS Wofsy D Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice Clin Immunol Immunopathol 1989, 52:421-434. 10.1016/0090-1229(89)90157-8 2758698
11. Gordon C Wofsy D Effects of recombinant murine tumor necrosis factor-alpha on immune function J Immunol 1990, 144:1753-1758. 2307839
12. Kontoyiannis D Kollias G Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor Eur J Immunol 2000, 30:2038-2047. 10.1002/ 1521-4141(200007)30:7<2038::AID-IMMU2038>.3.0.CO;2-K 10940893
13. Boswell JM Yui MA Burt DW Kelley VE Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis J Immunol 1988, 141:3050-3054. 3262676
14. Yokoyama H Kreft B Kelley VR Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms Kidney Int 1995, 47:122-130. 10.1038/ki.1995.14 7731137
15. Brennan DC Yui MA Wuthrich RP Kelley VE Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury J Immunol 1989, 143:3470-3475. 2584702
16. Edwards CK III Zhou T Zhang J Baker TJ De M Long RE Borcherding DR Bowlin TL Bluethmann H Mountz JD Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha J Immunol 1996, 157:1758-1772. 8759766
17. Deguchi Y Kishimoto S Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice Clin Exp Immunol 1991, 85:392-395. 1535595 1893619
18. Su X Zhou T Yang P Edwards CK Mountz JD Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor Arthritis Rheum 1998, 41:139-149. 10.1002/ 1529-0131(199801)41:1<139::AID-ART17>3.0.CO;2-T 9433879
19. Segal R Dayan M Zinger H Mozes E Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline Lupus 2001, 10:23-31. 10.1191/ 096120301675275538 11243506
20. Charles PJ Smeenk RJ De Jong J Feldmann M Maini RN Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials Arthritis Rheum 2000 43 2383 2390 10.1002/ 1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D 11083258
21. Kruithof E Van Den BF Baeten D Herssens A De Keyser F Mielants H Veys EM Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: One year follow up Ann Rheum Dis 2002, 61:207-212. 1754032 11830424 10.1136/ard.61.3.207
22. De Rycke L Kruithof E Van Damme N Hoffman IE Van den BN Van Den BF Veys EM De Keyser F Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy Arthritis Rheum 2003, 48:1015-1023. 10.1002/art.10876 12687543
23. Garcia-Planella E Domenech E Esteve-Comas M Bernal I Cabre E Boix J Gassull MA Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab) Eur J Gastroenterol Hepatol 2003, 15:351-354. 10.1097/00042737-200304000-00003 12655253
24. Ferraro-Peyret C Coury F Tebib JG Bienvenu J Fabien N Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: A two-year prospective study Arthritis Res Ther 2004, 6:R535-R543. 1064868 15535831 10.1186/ar1440
25. Vermeire S Noman M Van Assche G Baert F Van Steen K Esters N Joossens S Bossuyt X Rutgeerts P Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: A prospective cohort study Gastroenterology 2003, 125:32-39. 10.1016/S0016-5085(03)00701-7 12851868
26. Allanore Y Sellam J Batteux F Job DC Weill B Kahan A Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab Clin Exp Rheumatol 2004, 22:756-758. 15638051
27. Eriksson C Engstrand S Sundqvist KG Rantapaa-Dahlqvist S Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha Ann Rheum Dis 2005, 64:403-407. 10.1136/ard.2004.024182 15297281
28. De Rycke L Baeten D Kruithof E Van Den BF Veys EM De Keyser F Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis Arthritis Rheum 2005, 52:2192-2201. 10.1002/art.21190 15986349
29. Sellam J Allanore Y Batteux F Deslandre CJ Weill B Kahan A Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate Joint Bone Spine 2005, 72:48-52. 10.1016/ j.jbspin.2004.03.003 15681248
30. Atzeni F Ardizzone S Sarzi-Puttini P Colombo E Maconi G De PS Carrabba M Bianchi PG Autoantibody profile during short-term infliximab treatment for Crohn's disease: A prospective cohort study Aliment Pharmacol Ther 2005, 22:453-461. 10.1111/j.1365-2036.2005.02576.x 16128684
31. Comby E Tanaff P Mariotte D Costentin-Pignol V Marcelli C Ballet JJ Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy J Rheumatol 2006, 33:24-30. 16395746
32. De Bandt M Sibilia J Le LX Prouzeau S Fautrel B Marcelli C Boucquillard E Siame JL Mariette X Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey Arthritis Res Ther 2005, 7:R545-R551. 1174953 15899041 10.1186/ar1715
33. Ferraccioli GF Assaloni R Di Poi E Gremese E De Marchi G Fabris M Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: Results of an open trial Rheumatology (Oxford) 2002, 41:1109-1112. 10.1093/rheumatology/ 41.10.1109 12364628
34. Ferraccioli GF Assaloni R Perin A Drug-induced systemic lupus erythematosus and TNF-alpha blockers Lancet 2002, 360:645. 10.1016/ S0140-6736(02)09798-2 12241963
35. Colombel JF Loftus EV Jr Tremaine WJ Egan LJ Harmsen WS Schleck CD Zinsmeister AR Sandborn WJ The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients Gastroenterology 2004, 126:19-31. 10.1053/j.gastro.2003.10.047 14699483
36. Ramos-Casals M Brito-Zeron P Munoz S Soria N Galiana D Bertolaccini L Cuadrado MJ Khamashta MA Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases Medicine (Baltimore) 2007, 86:242-251. 10.1097/MD.0b013e3181441a68 17632266
37. Carlson E Rothfield N Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis Arthritis Rheum 2003, 48:1165-1166. 10.1002/art.11033 12687569
38. Mor A Bingham C III Barisoni L Lydon E Belmont HM Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept J Rheumatol 2005, 32:740-743. 15801034
39. Stokes MB Foster K Markowitz GS Ebrahimi F Hines W Kaufman D Moore B Wolde D D'Agati VD Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis Nephrol Dial Transplant 2005, 20:1400-1406. 10.1093/ndt/gfh832 15840673
40. Maury CP Teppo AM Tumor necrosis factor in the serum of patients with systemic lupus erythematosus Arthritis Rheum 1989, 32:146-150. 10.1002/ anr.1780320206 2920050
41. Studnicka-Benke A Steiner G Petera P Smolen JS Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus Br J Rheumatol 1996, 35:1067-1074. 10.1093/rheumatology/35.11.1067 8948291
42. Gabay C Cakir N Moral F Roux-Lombard P Meyer O Dayer JM Vischer T Yazici H Guerne PA Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity J Rheumatol 1997, 24:303-308. 9034987
43. Davas EM Tsirogianni A Kappou I Karamitsos D Economidou I Dantis PC Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTN-Falpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus Clin Rheumatol 1999, 18:17-22. 10.1007/s100670050045 10088943
44. Aringer M Stummvoll GH Steiner G Koller M Steiner CW Hofler E Hiesberger H Smolen JS Graninger WB Serum interleukin-15 is elevated in systemic lupus erythematosus Rheumatology (Oxford) 2001, 40:876-881. 10.1093/ rheumatology/40.8.876 11511756
45. Aderka D Wysenbeek A Engelmann H Cope AP Brennan F Molad Y Hornik V Levo Y Maini RN Feldmann M Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus Arthritis Rheum 1993, 36:1111-1120. 10.1002/art.1780360812 8393677
46. Aringer M Feierl E Steiner G Stummvoll GH Höfler E Steiner CW Radda I Smolen JS Graninger WB Increased bioactive TNF in human systemic lupus erythematosus: Associations with cell death Lupus 2002, 11:102-108. 10.1191/0961203302lu160oa 11958572
47. Takemura T Yoshioka K Murakami K Akano N Okada M Aya N Maki S Cellular localization of inflammatory cytokines in human glomerulonephritis Virchows Arch 1994, 424:459-464. 10.1007/BF00191429 8032526
48. Malide D Russo P Bendayan M Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients Hum Pathol 1995, 26:558-564. 10.1016/0046-8177(95)90253-8 7750940
49. Neale TJ Ruger BM Macaulay H Dunbar PR Hasan Q Bourke A Murray-McIntosh RP Kitching AR Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy Am J Pathol 1995, 146:1444-1454. 1870891 7778683
50. Herrera-Esparza R Barbosa-Cisneros O Villalobos-Hurtado R Avalos-Diaz E Renal expression of IL-6 and TNFalpha genes in lupus nephritis Lupus 1998, 7:154-158. 10.1191/096120398678919949 9607638
51. Aringer M McInnes IB Steiner G Soleiman A Stöckl-Hiesleitner S Hoefler E Meyer B Ulrich W Smolen JS TNF and interleukin-18 (IL-18) upregulation in kidneys and sera of patients with active systemic lupus erythematosus [abstract] Ann Rheum Dis 2007, 66:108.
52. Zampieri S Alaibac M Iaccarino L Rondinone R Ghirardello A Sarzi-Puttini P Peserico A Doria A Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus Ann Rheum Dis 2006, 65:545-548. 10.1136/ard.2005.039362 16096331
53. Smolen JS Strand V Cardiel M Edworthy S Furst D Gladman D Gordon C Isenberg DA Klippel JH Petri M et al.: Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains J Rheumatol 1999, 26:504-507. 9972996
54. Elliott MJ Maini RN Feldmann M Long-Fox A Charles P Bijl H Woody JN Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis Lancet 1994, 344:1125-1127. 10.1016/S0140-6736(94)90632-7 7934495
55. Brandt J Haibel H Cornely D Golder W Gonzalez J Reddig J Thriene W Sieper J Braun J Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab Arthritis Rheum 2000 43 1346 1352 10.1002/ 1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E 10857793
56. Aringer M Graninger WB Steiner G Smolen JS Safety and efficacy of TNFa blockade in systemic lupus erythematosus - an open label study Arthritis Rheum 2004, 50:3161-3169. 10.1002/art.20576 15476222
57. Gonzalez CM Lopez-Longo FJ Monteagudo I Vazquez-Coleman J Montoro M Ortega C Nuno L Gonzalez-Diaz de Rabago E de la Torre-Ortega I Carreno L Anti-TNF agents are effective and safe in the management of systemic lupus erythematosus [abstract] Arthritis Rheum 2004, 50:S412.
58. Micheloud D Nuno L Rodriguez-Mahou M Sanchez-Ramon S Ortega MC Aguaron A Junco E Carbone J Fernandez-Cruzl E Carreno L Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy Lupus 2006, 15:881-885. 10.1177/0961203306070970 17211995
59. Aringer M Houssiau F Graninger WB Feierl E Steiner G Smolen JS Long term safety and efficacy of open-label infliximab for SLE [abstract] Ann Rheum Dis 2007, 66:455.
60. Hayat SJ Uppal SS Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus Mod Rheumatol 2007, 17:174-177. 10.1007/s10165-006-0561-8 17437178
61. Hayat SJ Uppal SS Narayanan Nampoory MR Johny KV Gupta R Al-Oun M Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis Clin Rheumatol 2007, 26:973-975. 10.1007/s10067-006-0219-0 16565897
62. Aringer M Steiner G Graninger WB Hofler E Steiner CW Smolen JS Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus Arthritis Rheum 2007, 56:274-279. 10.1002/art.22327 17195231
63. Katz RS Holt-Daly N MacDonald PA Frequent infusion reactions associated with infliximab treatment in patients with polyarthritis related to systemic lupus erythematosus [abstract] Arthritis Rheum 2003, 48:S379.
64. Hiepe F Bruns A Feist E Burmester GR Successful treatment of a patient suffering from a refractory subacute cutaneous lupus erthematosus (SCLE) with blockers of tumour necrosis factor a [abstract] Arthritis Rheum 2004, 50:S413. 10.1002/art.20055
65. Norman R Greenberg RG Jackson JM Case reports of etanercept in inflammatory dermatoses J Am Acad Dermatol 2006, 54:S139-S142. 10.1016/ j.jaad.2005.11.1090 16488329
66. Lejeune FJ Clinical use of TNF revisited: Improving penetration of anti-cancer agents by increasing vascular permeability J Clin Invest 2002, 110:433-435. 150423 12189235 10.1172/JCI200216493
67. Aringer M Graninger WB Steiner G Smolen JS Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study Arthritis Rheum 2004, 50:3161-3169. 10.1002/art.20576 15476222
68. Arbuckle MR McClain MT Rubertone MV Scofield RH Dennis GJ James JA Harley JB Development of autoantibodies before the clinical onset of systemic lupus erythematosus N Engl J Med 2003, 349:1526-1533. 10.1056/ NEJMoa021933 14561795
69. Palucka AK Blanck JP Bennett L Pascual V Banchereau J Cross-regulation of TNF and IFN-alpha in autoimmune diseases Proc Natl Acad Sci USA 2005, 102:3372-3377. 552921 15728381 10.1073/pnas.0408506102
70. Via CS Shustov A Rus V Lang T Nguyen P Finkelman FD In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL J Immunol 2001, 167:6821-6826. 11739498
71. Pittoni V Bombardieri M Spinelli FR Scrivo R Alessandri C Conti F Spadaro A Valesini G Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13 Ann Rheum Dis 2002, 61:723-725. 1754194 12117680 10.1136/ard.61.8.723
72. Cope AP Londei M Chu NR Cohen SB Elliott MJ Brennan FM Maini RN Feldmann M Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis J Clin Invest 1994, 94:749-760. 296155 8040330
73. Isomaki P Panesar M Annenkov A Clark JM Foxwell BM Chernajovsky Y Cope AP Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex at the cell surface J Immunol 2001, 166:5495-5507. 11313388
74. Casciola-Rosen L Rosen A Petri M Schlissel M Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implications for coagulation events and antigenic spread in systemic lupus erythematosus Proc Natl Acad Sci USA 1996, 93:1624-1629. 39992 8643681 10.1073/ pnas.93.4.1624
75. Utz PJ Hottelet M Schur PH Anderson P Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus J Exp Med 1997, 185:843-854. 10.1084/jem.185.5.843 9120390
76. ClinicalTrials.gov home page http://www.clinicaltrials.gov